Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 27;7(1):16379.
doi: 10.1038/s41598-017-16419-w.

Virus replicon particle vaccines expressing nucleoprotein of influenza A virus mediate enhanced inflammatory responses in pigs

Meret E Ricklin  1 , Sylvie Python  1 , Nathalie J Vielle  1 , Daniel Brechbühl  1 , Beatrice Zumkehr  1 , Horst Posthaus  2   3 , Gert Zimmer  1 , Nicolas Ruggli  1 , Artur Summerfield  4   5
Affiliations

Virus replicon particle vaccines expressing nucleoprotein of influenza A virus mediate enhanced inflammatory responses in pigs

Meret E Ricklin et al. Sci Rep. .

Abstract

Studies in the mouse model indicate that the nucleoprotein of influenza A virus represents an interesting vaccine antigen being well conserved across subtypes of influenza virus but still able to induce protective immune responses. Here we show that immunizations of pigs with vesicular stomatitis virus- and classical swine fever virus-derived replicon (VRP) particles expressing the nucleoprotein (NP) of H1N1 A/swine/Belzig/2/01 induced potent antibody and T-cell responses against influenza A virus. In contrast to a conventional whole inactivated virus vaccine, the VRP vaccines induced both NP-specific CD4 and CD8 T cells responses, including interferon-γ and tumor-necrosis-factor dual-secreting cell. Although T-cells and antibody responses were cross-reactive with the heterologous H1N2 A/swine/Bakum/R757/2010 challenge virus, they did not provide protection against infection. Surprisingly, vaccinated pigs showed enhanced virus shedding, lung inflammation and increased levels of systemic and lung interferon-α as well as elevated lung interleukin-6. In conclusion, our study shows that NP, although efficacious in the mouse model, appears not to be a promising stand-alone vaccine antigen for pigs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
VRP vector mediated NP expression and induce NP-specific antibodies in pigs. (a) BHK-21 cells infected by VSV*ΔG-NP express NP. The left plot demonstrates GFP expression only after infection with VSV*ΔG, and the right plot GFP/NP double positive cells after infection with VSV*ΔG-NP. (b) Overlay histogram of SK-6 cells infected with CSFVΔErns (blue histogram) and CSFVΔErns-NP (red histogram). (c) Kinetics of NP antibody responses induced by VRP and WIV vaccines determined by ELISA. Pigs were vaccinated with either VSV*ΔG-NP, CSFVΔErns-NP, empty vectors or WIV vaccines, and immune sera collected at different time points and tested by ELISA. Titers were determined as the highest serum dilution leading to photometric values above the detection threshold. The pigs received a booster immunization at day 28. (d) Reactivity of sera collected at day 48 after VRP vaccination with MDBK cells infected with Belzig (H1N1, homologous virus), R757/10 (H1N2, heterologous challenge virus) or mock. In the upper row, representative results for sera from the VSV VRP vector-immunized pigs, and in the lower row results from the CSFV VRP-immunized animals are shown. The blue histograms represent mock-infected cells, and is overlaid with the red histograms representing the reactivity with virus-infected cells. (e) Reactivity of all sera from VSV*ΔG-NP, CSFVΔErns-NP and empty vectors injected pigs with Belzig (H1N1)- or R757/10 (H1N2)-infected MDCK cells, determined as described in Fig. 1d. Statistical significant differences between two groups were calculated using unpaired one-way ANOVA followed by Tukey’s multiple comparisons test (***P < 0.0001; **P < 0.005; *P < 0.05).
Figure 2
Figure 2
Peripheral blood CD4 and CD8 T-cell responses induced by VRP and WIV vaccines. PBMC were isolated at day 48 post vaccination (20 days after the booster injection) and re-stimulated in vitro with CAF or R757/10 (H1N2) virus to determine the percentage of virus-specific IFNγ (a,d), TNF (b,e) and dual cytokine (c,f) producing T cells in both the CD4 (A–C) and the CD8 (d–f) T cell subset. Asterisks indicate significant differences between two groups as calculated using unpaired one-way ANOVA followed by Tukey’s multiple comparisons test (***P < 0.0001; **P < 0.005; *P < 0.05).
Figure 3
Figure 3
Body temperature following heterologous challenge. VSV*ΔG-NP, CSFVΔErns-NP, empty vectors or WIV-vaccinated animals were challenged with R757/10 (H1N2). In (a), mean values and standard deviations of body temperatures are shown for each group. In (b), values for individual animals are shown for day 2 p.i. Asterisks indicate significant differences between two groups as calculated using unpaired one-way ANOVA followed by Tukey’s multiple comparisons test (***P < 0.0001; **P < 0.005; *P < 0.05).
Figure 4
Figure 4
Lung lesions after challenge infection. Lung lesions were assessed microscopically from each lobe at three days p.i. with R757/10 (H1N2). Scores were determined in a blinded manner by an even-handed pathologist for each lobe, and pooled to one value per animal. Asterisks indicate significant differences between two groups as calculated using unpaired one-way ANOVA followed by Tukey’s multiple comparisons test (***P < 0.0001; **P < 0.005; *P < 0.05).
Figure 5
Figure 5
Viral RNA loads after challenge infection. Viral RNA copies/ml were quantified by RT-qPCR in swabs on days one (a), two (b) and three (c), in BAL fluid on day one (d) and day three (e), and in lung tissue on day three (f) p.i. with R757/10 (H1N2). Asterisks indicate significant differences between two groups as calculated using unpaired one-way ANOVA followed by Tukey’s multiple comparisons test (***P < 0.0001; **P < 0.005; *P < 0.05).
Figure 6
Figure 6
In vivo IFN-α responses after challenge infection. IFN-α levels were determined by ELISA in serum of infected animals on days one (a), two (b) and three (a), in BAL fluid on day one (d) and day three (e), and in lung tissue on day three (f) p.i. with R757/10 (H1N2). Asterisks indicate significant differences between two groups as calculated using unpaired one-way ANOVA followed by Tukey’s multiple comparisons test (***P < 0.0001; **P < 0.005; *P < 0.05).
Figure 7
Figure 7
In vivo IL-6 and IL-1β responses in the lung after heterologous challenge. Levels of the inflammatory cytokines IL-6 (a) and Il-1β (b) were determined by ELISA in lung homogenates prepared on day three p.i. with R757/10 (H1N2). Asterisks indicate significant differences between two groups as calculated using unpaired one-way ANOVA followed by Tukey’s multiple comparisons test (***P < 0.0001; **P < 0.005; *P < 0.05).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zheng M, Luo J, Chen Z. Development of universal influenza vaccines based on influenza virus M and NP genes. Infection. 2014;42:251–262. doi: 10.1007/s15010-013-0546-4. - DOI - PubMed
    1. Wraith DC, Vessey AE, Askonas BA. Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol. 1987;68(Pt 2):433–440. doi: 10.1099/0022-1317-68-2-433. - DOI - PubMed
    1. Fu TM, Friedman A, Ulmer JB, Liu MA, Donnelly JJ. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J Virol. 1997;71:2715–2721. - PMC - PubMed
    1. Chen Z, et al. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol. 1999;80(Pt 10):2559–2564. doi: 10.1099/0022-1317-80-10-2559. - DOI - PubMed
    1. Epstein SL, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine. 2005;23:5404–5410. doi: 10.1016/j.vaccine.2005.04.047. - DOI - PubMed

Publication types

MeSH terms